Table 1 Clinical features of MPN patients
From: Potential application of the bulk RNA sequencing in routine MPN clinics
ID | Gender | Age (Years) | Source of sample | Driver gene mutation | JAK2V617F Mutation burden | LDH(IU/mL) | WT1Â expression (WT1/104 copies ABL1) | WBC(109/L) | HGB(g/L) | PLT(1012/L) |
|---|---|---|---|---|---|---|---|---|---|---|
PV1 | M | 75 | BM | JAK2 | 78.77% | 246 | 0.20% | 17.23 | 177.8 | 631 |
PV2 | F | 59 | BM | JAK2 | 53.44% | 337 | 0.39% | 10.01 | 173.1 | 543 |
PV3 | M | 67 | BM | JAK2 | 10.8% | NA | 0.16% | NA | NA | NA |
ET1 | M | 52 | BM | JAK2 | 12.73% | NA | 0.23% | NA | NA | NA |
ET2 | F | 55 | BM | Triple negative | NA | 138 | 0.06% | 8.2 | 111 | 889 |
ET3 | M | 52 | BM | JAK2 | 20.55% | 154 | 0.20% | 6.75 | 144.3 | 694 |
ET4 | F | 75 | BM | JAK2 | 21.58% | 269 | 0.02% | 10.2 | 123 | 612 |
ET5 | F | 68 | BM | Triple negative | NA | NA | 0.02% | NA | NA | NA |
ET6 | F | 78 | BM | JAK2 | 6.23% | 193 | 0.26% | 6.3 | 130.6 | 576 |
PBET1 | F | 87 | PB | JAK2 | 10.47% | NA | 0 | NA | NA | NA |
PBET2 | M | 66 | PB | JAK2 | 0.01% | NA | 0 | 6.62 | 111.5 | 426 |
ET7 | M | 67 | BM | JAK2 | 4.32% | 181 | 0.09% | 7.93 | 50.3 | 745 |
ET8 | F | 63 | BM/PB | JAK2 | 7.50% | NA | 0.11% | 5.8 | 124 | 554 |
ET9 | M | 35 | BM | JAK2 | 22.7% | 311 | 0.001 | 13.5 | 159 | 613 |
ET10 | F | 56 | BM/PB | JAK2 | 0.02% | NA | 0 | 7.24 | 142.3 | 490 |
ET11 | M | 76 | BM | JAK2 | 35.11% | 248 | 0.15% | 10.4 | 132 | 647 |
ET12 | F | 65 | BM | CALR | 0 | 350 | 0.14% | 14.43 | 126 | 1948 |
ET13 | M | 74 | BM | JAK2 | 32.49% | 277 | 0 | 11.6 | 90 | 1235 |
ET14 | M | 70 | BM | JAK2 | 71.53% | 531 | 1.93 | 20.83 | 183 | 822 |
ET15 | F | 72 | BM | JAK2 | 7.04% | 183 | 0.31% | 6.45 | 182 | 633 |
ET16 | F | 57 | BM | Triple negative | NA | 282 | NA | 10.02 | 141 | 547 |
PBET3 | F | 52 | PB | JAK2 | 4.07% | NA | 0 | 7.59 | 143 | 566 |
PBET4 | M | 33 | PB | JAK2 | 2.55% | NA | 0 | 9.83 | 162 | 561 |
ET17 | M | 74 | BM | JAK2 | 39.30% | 389 | 0.03% | 12 | 126 | 689 |
ET18 | M | 74 | BM | JAK2 | 11.14% | 171 | 0.07% | 10.6 | 118 | 869 |
ET19 | F | 58 | BM | JAK2 | 37.34% | 293 | 0.26% | 7.9 | 129 | 836 |
PMF1 | M | 56 | BM | JAK2 | 75.99% | NA | 0.41% | 16.87 | 93.6 | 883 |
PMF2 | M | 64 | BM | JAK2 | 57.70% | 234 | 0.15% | 15 | 173 | 501 |
PMF3 | M | 66 | BM | JAK2 | 73.30% | 252 | 1.99% | 11 | 62 | 251 |
PMF4 | M | 64 | BM | JAK2 | 13.35% | NA | 0.07% | NA | NA | NA |
PMF5 | M | 57 | BM | JAK2 | 43.99% | 280 | 0.69% | 10.16 | 76.9 | 522 |
PMF6 | M | 48 | BM | JAK2 | 90.87% | 437 | 3.06% | 14.63 | 159.5 | 241 |
PMF7 | M | 80 | BM | JAK2 | 72.29% | NA | 5.51% | NA | NA | NA |
PMF8 | M | 65 | BM | JAK2 | 97.60% | NA | 1.34% | 9.7 | 89 | 408 |